Myasthenia Gravis Flashcards
1
Q
Definition of MG
A
- Autoimmune condition that causes muscle weakness that gets progressively worse with activity and improves with rest
- Affects women at 40 years and men at 60 years
- Strong link with thymomas
2
Q
Pathophysiology of MG
A
- Motor nerves communicate with muscles at the NMJ
- At the NMJ, axons of motor nerves are situated across a synapes from the post-synaptic membrane of the muscle cell
- Axons release a neurotransmitter from the pre-synaptic membrane called acetylcholine (ACh)
- ACh attaches to receptors on the post-synaptic membrane, stimulating them and causing muscle contraction
- In MG, ACh receptor antibodies are produced which bind to the post-synaptic NMJ receptors and lock the action of ACh
- These antibodies also activate the complement system within the NMJ causing damage to the post-synaptic membrane
3
Q
Presentation of MG
A
- Symptoms mostly affect proximal muscles and small muscles of the head and neck
- Extraocular muscle weakness causing diplopia
- Eyelid weakness causing ptosis
- Weakness of the facial movements
- Difficulty swallowing
- Fatigue in the jaw when chewing
- Slurred speech
- Progressive weakness with repetitive movements
4
Q
Diagnosis of MG
A
- On examination check for thymectomy scar, repeated blinking will exacerbate ptosis, check upward gaze for diplopia, repeat abduction of one arm 20 times (reduced movement) and check FVC on spirometry
- Acetylcholine receptor (ACh-R) antibodies
- Muscle-specific kinase (MuSK) antibodies
- LRP4 antibodies
- CT/MRI of the thymus for thymoma
- Edrophonium test (neostigmine) increases amount of ACh and temporarily releaves symptoms
5
Q
Management of MG
A
- Reversible acetylcholinesterase inhibitors (pyridostigmine or neostigmine) increases levels of ACh
- Immunosuppression (prednisolone or azathioprine) suppresses production of anitbodies
- Thymectomy
- Monoclonal antibodies (rituximab, eculizumab)
6
Q
Myasthenic crisis
A
- Causes an acute worsening of symptoms
- Often triggered by other illnesses such as RTIs
- Can lead to respiratory failure due to weakness of respiratory muscles
- May require NIV with BiPAP or intubation and ventilation
- Medical treatments include immunomodulatory therapies such as IVIG and plasma exchange